SynthesisPharmacoEconomics - open2022
Community Distribution of Naloxone: A Systematic Review of Economic Evaluations.
Synthesis in PharmacoEconomics - open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Recruiting a National Sample of First Response Agencies to Participate in an Overdose Prevention Research Project: Randomized Controlled Trial and Feasibility Study.JMIR formative research · 2026Trial
- A scoping review of emergency department take-home naloxone on patient and health outcomes.CJEM · 2026Article
- Door-to-door overdose harm reduction: an Illinois case study.Harm reduction journal · 2024Article
- Naloxone Dispensing to Youth Ages 10-19: 2017-2022.Pediatrics · 2024Article
- Statewide efforts to address the opioid epidemic: Results from a national survey of single state agencies.Journal of substance use and addiction treatment · 2024Article
- Drug Deactivation Pouches for Primary Prevention of Opioid Overdose: Perceptions and Attitudes of Community Members.Journal of the American Board of Family Medicine : JABFM · 2024Article
- Association of opioid or other substance use disorders with health care use among patients with suicidal symptoms.Journal of substance use and addiction treatment · 2024Article
- Take-Home Naloxone Access and Use among Older Adults Living with Pain: A Scoping Review.The Canadian journal of hospital pharmacy · 2024Article
- Article
- Guidance on take-home naloxone distribution and use by community overdose responders in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023Article
- Addressing the Opioid Crisis-The Need for a Pain Management Intervention in Community Pharmacies in Canada: A Narrative Review.Pharmacy (Basel, Switzerland) · 2023Review
- The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City.Drug and alcohol dependence reports · 2022Article
- An economic evaluation of community pharmacy-dispensed naloxone in Canada.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPCArticle
- Barriers and Facilitators to Naloxone Access for Adolescents: A Narrative Review.Substance use : research and treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a core component of harm-reduction strategies to address the opioid crisis, several countries have instituted publicly funded programs to distribute naloxone for lay administration in the community. The effectiveness in reducing mortality from opioid overdose has been demonstrated in multiple systematic reviews. However, the economic impact of community naloxone distribution programs is not fully understood.
objectivesOur objective was to conduct a review of economic evaluations of community distribution of naloxone, assessing for quality and applicability to diverse contexts and settings. DATA SOURCES: The search strategy was performed on MEDLINE, Embase, and EconLit databases. STUDY ELIGIBILITY CRITERIA AND
interventionsSearch criteria were developed based on two themes: (1) papers involving naloxone or narcan and (2) any form of economic evaluation. A focused search of the grey literature was also conducted. Studies exploring the intervention of community distribution of naloxone were selected. STUDY APPRAISAL AND SYNTHESIS
methodsData extraction was done using the British Medical Journal guidelines for economic submissions, assigning quality levels based on the impact of the missing or unclear components on the strength of the conclusions.
resultsA total of nine articles matched our inclusion criteria: one cost-effectiveness analysis, eight cost-utility analyses, and one cost-benefit analysis. Overall, the quality of the studies was good (six of high quality, two of moderate quality, and one of low quality). All studies concluded that community distribution of naloxone was cost effective, with an incremental cost-utility ratio range of $US111-58,738 (year 2020 values) per quality-adjusted life-year gained. LIMITATIONS: Our search strategy was developed iteratively, rather than following an a priori design. Additionally, our search was limited to English terms. CONCLUSIONS AND IMPLICATIONS OF KEY
findingsBased on this review, community distribution of naloxone is a worthwhile investment and should be considered by other countries dealing with the opioid epidemic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.